New Delhi: Eli Lilly's diabetes and obesity drug Mounjaro (Tirzepatide) has become India's top-selling drug by value for October 2025, overtaking long-time leaders in the antidiabetic and cardiac therapy segments, according to the latest PharmaTrac Industry Mailer and IPM Performance Report for MAT October 2025.

As per PharmaTrac and industry data, Mounjaro recorded nearly ₹100 crore in sales in October 2025, the highest for any brand that month in the Indian Pharmaceutical Market (IPM). This puts it ahead of traditional market leaders such as Augmentin, which posted around ₹80 crore, and other top brands like Glycomet GP and Dolo-650.

Since its March 2025 launch, the GLP-1 receptor agonist has generated a cumulative ₹333 crore, marking one of the fastest scale-ups ever achieved by a ne

See Full Page